Supplemental Table S5. Association of Clinical Characteristics with Duration of GH Treatment Interruption (Years) after 1 Year of Treatment Resumption

Outcome variable	Unadjusted, β (95% CI)	Adjusted, β (95% CI)[b]
Body mass index, kg/m^2	0.16 (−0.08 to 0.40)	−0.03 (−0.34 to 0.27)
Body mass index Z-score	0.06 (−0.03 to 0.14)	0.00 (−0.09 to 0.08)
IGF-1, μg/L	−4.23 (−9.90, 1.44)	1.56 (−5.46 to 8.58)
IGFBP-3, μg/L	−58.25 (−106.60 to −9.90)[a]	−31.85 (−97.12 to 33.43)
Fasting glucose, mg/dL	0.98 (−0.24 to 2.20)	1.19 (−0.43 to 2.81)
Glycated hemoglobin, %	0.02 (−0.02 to 0.07)	0.02 (−0.04 to 0.08)
Total cholesterol, mg/dL	2.73 (0.78 to 4.68)[a]	0.98 (−1.59 to 3.55)
Triglyceride, mg/dL	2.24 (−2.79 to 7.27)	2.88 (−3.66 to 9.42)
HDL cholesterol, mg/dL	−0.02 (−1.27 to 1.23)	0.06 (−1.58 to 1.69)
LDL cholesterol, mg/dL	1.14 (−1.70 to 3.98)	0.31 (−3.59 to 4.21)
Non-HDL cholesterol, mg/dL	2.15 (−0.77 to 5.08)	0.37 (−3.51 to 4.25)

GH, growth hormone; CI, confidence interval; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

[a]$P<0.05$; [b]Models were adjusted for age, sex, peak growth hormone levels at re-evaluation for body mass index and body mass index Z-scores; the models were adjusted for age, sex, body mass index Z-scores, and peak GH levels for other parameters.